BCIQ Profiles

Company Profile Report
0520 Numab
BioCentury & Getty Images


Departing from its partner-heavy strategy, Numab raises $110M crossover round to push multispecific pipeline into the clinic

May 20, 2021 | 11:50 PM GMT

After years of building the company largely on non-dilutive partnership revenues, Numab has taken the plunge with a CHF100 million ($110.8 million) series C round to push its wholly-owned pipeline

Read the full 583 word article

How to gain access

Continue reading with a
two-week free trial.